NASDAQ:REPLReplimune Group Stock Price, Forecast & News

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPL stock has increased by 85.8% and is now trading at $22.16. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Replimune Group.

Replimune Group is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Replimune Group.

Replimune Group Inc (NASDAQ:REPL) released its quarterly earnings data on Wednesday, June, 3rd. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.04. View Replimune Group's earnings history.

7 equities research analysts have issued 1 year target prices for Replimune Group's shares. Their forecasts range from $12.50 to $40.00. On average, they expect Replimune Group's share price to reach $26.79 in the next year. This suggests a possible upside of 20.9% from the stock's current price. View analysts' price targets for Replimune Group.

Headlines about REPL stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Replimune Group earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the near term. View the latest news about Replimune Group.

Some companies that are related to Replimune Group include Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Alector (ALEC), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), I-Mab (BDTX), Sorrento Therapeutics (SRNE), Regenxbio (RGNX), Mesoblast (MESO), Sangamo Therapeutics (SGMO) and Cortexyme (CRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Peabody Energy (BTUUQ), Myovant Sciences (MYOV), Pfizer (PFE), Fate Therapeutics (FATE), Immunomedics (IMMU), AbbVie (ABBV), Aerie Pharmaceuticals (AERI), Axsome Therapeutics (AXSM) and Cleveland-Cliffs (CLF).

(REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REPL stock can currently be purchased for approximately $22.16.

Replimune Group has a market capitalization of $815.04 million. The company earns $-52,630,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Replimune Group employs 62 workers across the globe.

The official website for Replimune Group is www.replimune.com.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]